CRUK / CCLG AT9283 in Paediatric Patients

• Research type

  Research Study

• Full title

  A CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours

• IRAS ID

  14388

• Contact name

  Philip Ross

• Sponsor organisation

  Cancer Research UK

• Eudract number

  2008-005542-23

• ISRCTN Number

  n/a

• Research summary

  Children and adolescents aged between two and eighteen years of age will receive AT9283, a new drug that is hoped will be effective against cancer, over a period of 72 hours by continuous intravenous infusion. The dose of AT9283 will be increased in a controlled fashion as further patients are treated until such time that the side-effects are deemed unacceptable. In this way, a maximum tolerated dose will be determined in order to continue further studies with AT9283.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  09/H0405/28

• Date of REC Opinion

  27 Jul 2009

• REC opinion

  Further Information Favourable Opinion